SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Irish Mothers Unite to Stop HPV Vaccine Assault on Their Children

By 2 Comments

SEO Press Releases

North Hollywood, CA, September 7, 2010 — The Mothers’ Alliance Ireland (MAI), a committee of Christian Democrats the Family First Party dedicated to protecting the rights of parents and the welfare of children, has spent almost a decade researching the HPV/cervical cancer link and is now actively protesting mandatory vaccination of adolescent girls. MAI and concerned mothers from various counties throughout Ireland have written letters to the media, passed out information leaflets, held public meetings and contacted public health officials and politicians protesting this legislation.

Although Ireland has historically been a country filled with political strife, when it comes to the health and safety of their children, Irish mothers set aside all political differences. That is just what is happening all across the country – concerned mothers and political activists have united to call a halt to the Irish HPV vaccination programme.

'We will continue to sell our patented drugs with India-specific pricing'

By 1 Comment

The Times of India

September 8, 2010

MSD India’s managing director KG Ananthakrishnan spoke to ET’s Khomba Singh on future strategy and shared his views on the Indian government’s proposals on contentious issues such as compulsory licensing, capping FDI in the sector and reviewing of certain sections of Indian patent laws. Excerpts:

Global drugmakers have lobbied hard for review of controversial Section 3(d) of Indian patent laws and patent linkages. MNCs, including Merck, are yet to publicly voice views on the proposal being evaluated by the government?

Prevalence of high-risk human papillomavirus among older women

By 1 Comment

PubMed.gov

Obstet Gynecol. 2008 Nov;112(5):979-89.

Lindau ST, Drum ML, Gaumer E, Surawska H, Jordan JA.

University of Chicago Department of Obstetrics and Gynecology, the University of Chicago Cancer Research Center, Chicago, IL 60637, USA. slindau@uchicago.edu
Abstract

OBJECTIVE: To estimate the prevalence, genotypes, and individual-level correlates of high-risk human papillomavirus (HPV) among women aged 57-85.

METHODS: Community-residing women (N=1,550), aged 57-85, were drawn from a nationally representative probability sample. In-home interviews and biomeasures, including a self-collected vaginal specimen, were obtained between 2005 and 2006. Specimens were analyzed for high-risk HPV DNA using Hybrid Capture 2; of 1,028 specimens provided, 1,010 were adequate for analysis. All samples testing positive were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization.

Irish Media Choose their "Child Vaccine Scandal"

By 1 Comment

ComeLook.org, 29 August 2010

In Ireland, apparently, a story only qualifies as a ‘Vaccine Scandal’ if it relates to a ‘trial’ vaccine, preferably from 40-50 years ago, and the words ‘vaccine’ and ‘injury’ are not associated in any way.

Last weekend saw saturation coverage on a ‘Child Vaccine Scandal’ from the early 1960’s involving vaccine trials carried out without parental consent in Irish church-run children’s homes.

The Irish Independent ran three articles over four days (here, here, and here).
The Irish Times also ran two front page pieces on the same weekend (here and here).

The articles were triggered by the revelation that a number of victims, who now live in the US, are preparing a class action suit in the US courts (against the Pharma company responsible for the drug trials) because repeated attempts to seek justice in Ireland have failed.

Merck Cancer Shot May Not Be Economical for All Women (Update1)

By Leave a Comment

Bloomberg

By Shannon Pettypiece – August 21, 2008 10:18 EDT

Aug. 21 (Bloomberg) — Merck & Co.’s Gardasil cervical cancer vaccine isn’t worth the cost for women over 18 years old, according to a study that may undercut the drugmaker’s marketing efforts for that age group.

Gardasil, available for girls and young women ages 9 to 26, makes economic sense for preteens because they are less likely to have the sexually transmitted virus that causes cervical cancer, said researchers in a study released by the New England Journal of Medicine. Still, the cost benefit depends on how long Gardasil’s protection lasts, they said.

News

Videos

Contact